Janssen’s Yondelis receives US FDA nod to treat patients with unresectable/metastatic LPS or LMS
The US Food and Drug Administration (FDA) has approved Janssen Biotech Inc’s Yondelis (trabectedin) for the treatment of patients with unresectable (unable... Read More